Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?

NCT05788094 is registered in ClinicalTrials.gov with Shoklo Malaria Research Unit as lead sponsor.

NCT NCT05788094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05788094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?
Lead sponsor
Shoklo Malaria Research Unit
Phase
Phase 4
Overall status
Recruiting
Start date
June 26, 2023
Completion date
August 31, 2026
Enrollment
606 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria, vivax, plasmodium vivax malaria